EP1｜醫療用大麻不是夢？脂肪肝的新療法你敢試嗎？

#TBAL與您分享---Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. J Hepatol. 2015 Jun;62(6):1382-90..📌Significance :The significance of this study lies in exploration of potential therapeutic agents for non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome, that are increasingly prevalent due to rising obesity rates. The study investigates the effects of cannabinoids, specifically THCV and CBD, for their potential to improve insulin sensitivity and lipid metabolism. This could lead to new pharmacological treatments for NAFLD, as effective therapies..📌Importance of lipidology :The effects of THCV and CBD on lipid levels were examined in a variety of in vitro and in vivo systems, with special emphasis on models of hepatosteatosis. Treatment also induced post-translational changes in a variety of proteins such as CREB, PRAS40, AMPKa2 and several STATs indicating increased lipid metabolism and, possibly, mitochondrial activity. They show here that both THCV and CBD reduce intracellular lipid levels in vitro in a model of hepatosteatosis and adipocytes, mobilize zebrafish embryo lipid yolk stores and inhibit hepatosteatosis in obese mice..📌Connectivity to other fields :The implications of this study consist of various fields beyond hepatology and metabolic research, including pharmacology, nutrition, and mental health. This highlights the interdisciplinary nature of metabolic research.-READ MOREhttps://pubmed.ncbi.nlm.nih.gov/25595882/Lipid Profilinghttps://www.t-bal.com/art....../group-3wMaXdj7KAt8ziTgHoRYtRTBAL 台灣活性脂質股份有限公司官網  ⁠https://www.t-bal.com/⁠粉絲臉書團  ⁠https://www.facebook.com/TBAL2017⁠YOUTUBE  ⁠https://www.youtube.com/@Taiwan-BioActive-Lipid⁠The recipient's phone：+886-4-2247-6758Customer service email：⁠[email protected]⁠Fax：04-2217-5362LINE ID：@722hneuu